留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝癌肝移植术后肿瘤复发与外周血调节性T细胞及细胞因子表达水平的关系

杨绍臻 周林 杜国盛 宋继勇 朱志东 封立魁 索龙龙 郑永根

杨绍臻, 周林, 杜国盛, 等. 肝癌肝移植术后肿瘤复发与外周血调节性T细胞及细胞因子表达水平的关系[J]. 器官移植, 2016, 7(5): 382-385. doi: 10.3969/j.issn.1674-7445.2016.05.010
引用本文: 杨绍臻, 周林, 杜国盛, 等. 肝癌肝移植术后肿瘤复发与外周血调节性T细胞及细胞因子表达水平的关系[J]. 器官移植, 2016, 7(5): 382-385. doi: 10.3969/j.issn.1674-7445.2016.05.010
Yang Shaozhen, Zhou Lin, Du Guosheng, et al. Correlation of tumor recurrence after liver transplantation for hepatocellular carcinoma with the expression levels of regulatory T cells and cytokines in peripheral blood[J]. ORGAN TRANSPLANTATION, 2016, 7(5): 382-385. doi: 10.3969/j.issn.1674-7445.2016.05.010
Citation: Yang Shaozhen, Zhou Lin, Du Guosheng, et al. Correlation of tumor recurrence after liver transplantation for hepatocellular carcinoma with the expression levels of regulatory T cells and cytokines in peripheral blood[J]. ORGAN TRANSPLANTATION, 2016, 7(5): 382-385. doi: 10.3969/j.issn.1674-7445.2016.05.010

肝癌肝移植术后肿瘤复发与外周血调节性T细胞及细胞因子表达水平的关系

doi: 10.3969/j.issn.1674-7445.2016.05.010
基金项目: 

国家自然科学基金 81370578

详细信息
    通讯作者:

    杜国盛,Email:duguosheng@medmail.com.cn

  • 中图分类号: R617, R735.7

Correlation of tumor recurrence after liver transplantation for hepatocellular carcinoma with the expression levels of regulatory T cells and cytokines in peripheral blood

More Information
  • 摘要:   目的  分析肝细胞癌(肝癌)肝移植术后肿瘤复发与调节性T细胞(Treg)及细胞因子表达水平的关系。  方法  以解放军第309医院2010年至2014年56例肝移植患者为研究对象。根据术后病理资料分为肝癌肝移植组(28例)和肝硬化肝移植组(肝硬化组,28例),肝癌肝移植组再根据术后患者有否肿瘤复发分为未复发组(8例)和复发组(20例)。比较各组患者外周血中Treg及调节性细胞因子[血管内皮生长因子(VEGF)、白细胞介素(IL)-2、IL-10、IL-12、转化生长因子(TGF)-β、干扰素(IFN)-γ]的表达水平。  结果  与肝硬化组比较,未复发组的IFN-γ、IL-12水平显著升高(均为P<0.05);复发组的Treg%、VEGF、IFN-γ、IL-10、TGF-β水平均显著升高,IL-2和IL-12水平明显降低(均为P<0.05)。与未复发组比较,复发组的Treg%、VEGF、IL-10、TGF-β水平均显著升高,IFN-γ、IL-2、IL-12水平明显降低(均为P<0.05)。  结论  Treg及细胞因子水平可作为肝癌肝移植术后肿瘤复发的预测指标。

     

  • 表  1  各组患者移植术后血清调节性细胞因子水平的比较

    Table  1.   Comparison of regulatory cytokine levels in each group of patients after transplantation

    组别 n Treg
    (%)
    VEGF
    (pg/ml)
    IFN-γ
    (pg/ml)
    IL-2
    (pg/ml)
    IL-10
    (ng/L)
    IL-12
    (ng/L)
    TGF-β
    ng/L)
    肝癌组
     未复发组 8 12.6±4.4 186±27 331±95a 232±39 33±10 14.1±2.4a 73±29
     复发组 20 23.6±6.3a, b 361±51a, b 90±10a, b 157±24a, b 111±5a, b 2.3±0.6a, b 190±17a, b
    肝硬化组 28 8.9±3.1 255±41 74±11 286±43 64±17 6.3±0.7 121±36
     注:与肝硬化组比较,aP < 0.05;与未复发组比较,bP < 0.05
    下载: 导出CSV
  • [1] Ozgur HH, Ercetin AP, Eliyatkin N, et al. Regulatory T cells and their prognostic value in hepatopancreatobiliary tumours[J]. Hepatogastroenterology, 2014, 61(135):1847-1851. http://cn.bing.com/academic/profile?id=2334970166&encoded=0&v=paper_preview&mkt=zh-cn
    [2] Chen X, Du Y, Huang Z.CD4+CD25+Treg derived from hepatocellular carcinoma mice inhibits tumor immunity[J]. Immunol Lett, 2012, 148(1):83-89. doi: 10.1016/j.imlet.2012.09.002
    [3] Ligocki AJ, Niederkorn JY. Advances on non-CD4+Foxp3+ T regulatory cells: CD8+, type 1, and double negative T regulatory cells in organ transplantation[J]. Transplantation, 2015, 99(8):1553-1559. doi: 10.1097/TP.0000000000000813
    [4] 杜国盛, 周林, 石炳毅, 等.三联抗肿瘤疗法预防晚期原发性肝癌肝移植术后肿瘤复发的临床研究[J].器官移植, 2014, 5(2):74-77. http://www.organtranspl.com/browse/detail/qkid/85/id/221.html

    Du GS, Zhou L, Shi BY, et al. Clinical study of triple anti-tumor therapy for preventing tumor recurrence of terminal primary liver cancer after liver transplantation[J]. Organ Transplant, 2014, 5(2):74-77. http://www.organtranspl.com/browse/detail/qkid/85/id/221.html
    [5] 杜国盛, 周林, 朱志东, 等. Foxp3+调节性T细胞与肝癌肝移植患者术后肿瘤复发关系的研究[J].器官移植, 2015, 6(5):310-315. http://www.organtranspl.com/browse/detail/cat/33/id/125

    Du GS, Zhou L, Zhu ZD, et al. Research on the relationship between Foxp3+ regulatory T cell and tumor recurrence of patients after liver transplantation for hepatocellular carcinoma[J]. Organ Transplant, 2015, 6(5):310-315. http://www.organtranspl.com/browse/detail/cat/33/id/125
    [6] Chen X, Du Y, Lin X, et al. CD4+CD25+ regulatory T cells in tumor immunity[J]. Int Immunopharmacol, 2016, 34:244-249. doi: 10.1016/j.intimp.2016.03.009
    [7] Teh PP, Vasanthakumar A, Kallies A, et al. Development and function of effector regulatory T cells[J]. Prog Mol Biol Transl Sci, 2015, 136:155-174. doi: 10.1016/bs.pmbts.2015.08.005
    [8] Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens[J]. World Allergy Organ J, 2015, 8(1):17. doi: 10.1186/s40413-015-0063-2
    [9] Hall BM. T cells: soldiers and spies-the surveillance and control of effector T cells by regulatory T cells[J]. Clin J Am Soc Nephrol, 2015, 10(11):2050-2064. doi: 10.2215/CJN.06620714
    [10] Li L, Yang C, Zhao Z, et al. Skewed T-helper (Th) 1/2-and Th17/T regulatory cell balances in patients with renal cell carcinoma[J]. Mol Med Rep, 2015, 11(2):947-953. http://www.sigmaaldrich.com/catalog/papers/25352158
    [11] Askar M. T helper subsets & regulatory T cells: rethinking the paradigm in the clinical context of solid organtransplantation[J]. Int J Immunogenet, 2014, 41(3):185-194. doi: 10.1111/iji.2014.41.issue-3
    [12] Liu KS, Fan XQ, Zhang L, et al. Effects of recombinant human interleukin-10 on Treg cells, IL-10 and TGF-β in transplantation of rabbit skin[J]. Mol Med Rep, 2014, 9(2):639-644. http://www.medscape.com/medline/abstract/24270972
    [13] Metidji A, Rieder SA, Glass DD, et al. IFN-α/β receptor signaling promotes regulatory T cell development and function under stress conditions[J]. J Immunol, 2015, 194(9):4265-4276. doi: 10.4049/jimmunol.1500036
    [14] Vahl JC, Drees C, Heger K, et al. Continuous T cell receptor signals maintain a functional regulatory T cell pool[J]. Immunity, 2014, 41(5):722-736. doi: 10.1016/j.immuni.2014.10.012
    [15] Zhao Y, Wu T, Shao S, et al. Phenotype, development, and biological function of myeloid-derived suppressor cells[J]. Oncoimmunology, 2015, 5(2):e1004983. https://www.ncbi.nlm.nih.gov/pubmed/27057424
    [16] Wang Y, Liu T, Tang W, et al. Hepatocellular carcinoma cells induce regulatory T Cells and lead to poor prognosis via production of transforming growth factor-β1[J]. Cell Physiol Biochem, 2016, 38(1):306-318. doi: 10.1159/000438631
    [17] Pandiyan P, Zhu J. Origin and functions of pro-inflammatory cytokine producing Foxp3+ regulatory T cells[J]. Cytokine, 2015, 76(1):13-24. doi: 10.1016/j.cyto.2015.07.005
    [18] 张志强, 贺杰峰, 张瑜, 等.大鼠肝癌免疫微环境中Treg与IL-10水平的变化及意义[J].当代医学, 2014, 20(4):18-19. http://mall.cnki.net/magazine/article/ddyi201404011.htm

    Zhang ZQ, He JF, Zhang Y, et al. The change and significance of the levels of Treg and IL-10 in immune microenvironment of rat with liver cancer[J]. Contemp Med, 2014, 20(4):18-19. http://mall.cnki.net/magazine/article/ddyi201404011.htm
  • 加载中
表(1)
计量
  • 文章访问数:  93
  • HTML全文浏览量:  36
  • PDF下载量:  11
  • 被引次数: 0
出版历程
  • 收稿日期:  2016-05-20
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2016-09-15

目录

    /

    返回文章
    返回